February 21, 2024 03:27 PM ESTUpdated February 21, 09:14 PM

Adaptive Biotechnologies trims handful of jobs as strategic review nears completion

Kyle LaHucik

Senior Reporter

Adaptive Biotechnologies, a Seattle-based diagnostics maker and drug discovery company, told Endpoints News it recently eliminated 6.7% of its workforce as part of its strategic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adaptive Biotechnologies trims handful of jobs as strategic review nears completion

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Adap­tive Biotech­nolo­gies trims hand­ful of jobs as strate­gic re­view nears com­ple­tion

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Adaptive Biotechnologies trims handful of jobs as strategic review nears completion